Best medication for muscle spasm, honestly

Oral baclofen is for spasticity from multiple sclerosis or spinal cord disease; its label states it is NOT indicated for muscle spasm from rheumatic disorders, and that efficacy in stroke, cerebral palsy and Parkinson's is not established. On boxed warnings, the form matters: the oral tablets carry NONE, while the intrathecal (implanted pump) form is a different product that does carry an FDA BOXED WARNING — abrupt discontinuation has caused high fever, rebound spasticity, rhabdomyolysis, multi-organ failure and death. The tablets are still not something to stop suddenly. Newer oral labels (Ozobax DS, Lyvispah) carry the severe-withdrawal content too, and abrupt withdrawal from oral baclofen has caused hallucinations and seizures — it is tapered, not stopped. It is excreted largely unchanged by the kidney and accumulates when kidney function is reduced. It sits outside the Beers muscle-relaxant criterion, but the 2023 AGS Beers update adds baclofen to its kidney-function table: avoid it when eGFR is under 60 mL/min because of encephalopathy risk, and if it cannot be avoided use the lowest effective dose and watch for altered mental status. The new recommendation turns on kidney function, not age alone — but being outside the muscle-relaxant criterion is not a clean bill of health either. Its label's first warning is neonatal: babies exposed throughout pregnancy have withdrawn hours to days after birth with increased muscle tone, tremor, jitteriness and seizures, and the label says to taper and stop baclofen before delivery. Its label carries the same functional caution as dantrolene's contraindication, one notch weaker: use with caution where spasticity is what sustains upright posture and balance in walking, or wherever that tone is being used to gain function.

Approved for spasticity, not for an acute strain. Its effect is short (half-life about 2.5 hours), so the label suggests reserving doses for the times of day when relief matters most. It is CONTRAINDICATED with STRONG CYP1A2 inhibitors as a class — ciprofloxacin and fluvoxamine are the labeled examples, not the whole list — a routine antibiotic course is enough to matter. It lowers blood pressure, can cause hallucinations, and is one of only three muscle relaxants NIH's LiverTox links clearly to clinically apparent liver injury; the label says to monitor ALT and stop if injury occurs. Do not stop it abruptly — the label says to taper to avoid rebound hypertension, tachycardia and hypertonia. Along with baclofen, it is explicitly carved out of the Beers muscle-relaxant criterion, though clearance still falls more than 50% when creatinine clearance is under 25 mL/min and it is cleared about 4 times more slowly in older adults. Two practical points the label makes: it lowers blood pressure enough that syncope has been reported, so the first doses and any increase are when to be careful about standing up; and the capsules and tablets are NOT interchangeable with food — switching form or taking it with a meal when you did not before changes how much you absorb. A second tier matters as much as the contraindicated one: the label says to AVOID tizanidine with less potent CYP1A2 inhibitors — zileuton, the antiarrhythmics amiodarone, mexiletine, propafenone and verapamil, cimetidine, famotidine, oral contraceptives, acyclovir and ticlopidine — unless it is clearly necessary, because hypotension, bradycardia or excessive drowsiness can follow.

The odd one out on every axis. It is the only drug here that acts directly on skeletal muscle rather than through the central nervous system, and it treats chronic spasticity from upper motor neuron disorders — spinal cord injury, stroke, cerebral palsy, multiple sclerosis — with the label stating it is not indicated for muscle spasm from rheumatic disorders. Oral dantrolene carries an FDA BOXED WARNING for hepatotoxicity: symptomatic hepatitis, fatal and non-fatal, has been reported; risk is far higher at 800 mg a day or more than at up to 400 mg; overt hepatitis appears most often between the third and twelfth month of therapy; and risk is greater in women, in people over 35, and in those taking other medicines, with a higher proportion of fatal hepatic events reported in elderly patients. LiverTox puts overt liver injury at about 0.4% of recipients. Liver function is monitored throughout treatment. Note that the intravenous form used for malignant hyperthermia is a different product and does not carry this boxed warning. Two absolute CONTRAINDICATIONS sit alongside the boxed warning: active hepatic disease such as hepatitis or cirrhosis, and — critically for spasticity — use where spasticity is being used to sustain upright posture and balance in locomotion, OR whenever it is being used to obtain or maintain increased function. That second clause is broader than it first sounds: it covers tone relied on for transfers, standing from a chair, or grip, not only for walking. The label also directs stopping after 45 days if there is no observable benefit, which is a hepatotoxicity-limiting rule rather than a scheduling one.

Often chosen as the gentler option — fewer anticholinergic effects than cyclobenzaprine, no controlled-substance status — but its own label says it “does not directly relax tense skeletal muscles in man” and that the effect “may be related to its sedative properties.” Its half-life is the shortest here at 1 to 2 hours, so it clears fastest but is dosed more often. Liver disease matters most: clearance fell about 70% in patients with alcohol-related cirrhosis. The label says it should not be used in women who are or may become pregnant unless the prescriber judges the benefit to outweigh the risk, citing reports of fetal and congenital abnormalities. Use with caution in myasthenia gravis on anticholinesterase drugs — the same condition that bars orphenadrine outright. Being the mild one does not exempt it: methocarbamol is on the 2023 AGS Beers list to avoid in older adults.

The most-prescribed option, and closely related to the tricyclic antidepressants in structure — it is not an antidepressant, but that kinship is where the dry mouth, drowsiness and constipation come from. Its label restricts it to short periods of up to 2 or 3 weeks, and states it is NOT effective for spasticity from cerebral or spinal cord disease. It is CONTRAINDICATED with an MAOI or within 14 days of one, in the acute recovery phase of a heart attack, in arrhythmias, heart block or conduction disturbances, in heart failure, and in hyperthyroidism. It carries a serotonin syndrome warning alongside SSRIs, SNRIs, tricyclics, tramadol and MAOIs, and anticholinergic caution in glaucoma or raised eye pressure and in urinary retention. Its half-life is about 18 hours — roughly 32 hours for the Amrix extended-release capsule, rising to about 50 hours for Amrix past age 65 — which is why next-morning grogginess is common. On the 2023 AGS Beers list of drugs to avoid in older adults; if the immediate-release tablet is used anyway, the label says start at 5 mg and titrate slowly — an instruction that cannot be followed with the Amrix extended-release capsule, which is not recommended in older adults or in liver impairment at all. In hepatic impairment exposure roughly doubles: the label directs caution and a 5 mg start in mild impairment, and does not recommend it in moderate or severe.

The one to know about. Carisoprodol is a Schedule IV controlled substance — the only controlled drug on this page — and the liver converts it to MEPROBAMATE, a sedative with its own abuse and dependence potential and a half-life of roughly 10 hours against about 2 hours for carisoprodol itself, so the sedation outlasts the parent drug. The label limits use to 2 or 3 weeks and documents abuse, misuse and criminal diversion; overdose can cause CNS and respiratory depression, seizures and death, and the risk rises sharply with alcohol or other depressants. It is CONTRAINDICATED in acute intermittent porphyria and in anyone who has reacted to a carbamate such as meprobamate, and withdrawal can follow prolonged use. On the 2023 AGS Beers list to avoid in older adults. It is still widely prescribed. The label also states that its efficacy, safety and pharmacokinetics have not been established in people over 65, and that reduced CYP2C19 activity — around 15 to 20% of some East Asian populations — raises exposure.

Reputed to be the least sedating, though its label uses the same wording as methocarbamol's: it “does not directly relax tense skeletal muscles in man” and the mode of action “may be related to its sedative properties.” It carries restrictions the others do not: CONTRAINDICATED in significantly impaired kidney or liver function, and in anyone with a known tendency to drug-induced, hemolytic or other anemias. It also carries a serotonin syndrome WARNING with SSRIs, SNRIs, tricyclics, triptans, tramadol, opioids and MAOIs — the same concern as cyclobenzaprine, which matters because metaxalone is often picked as the safe-seeming choice. Food changes it substantially and in the direction that matters here: with a high-fat meal peak level rose about 178% and total exposure about 120% (the half-life falling from roughly 9 hours to 2.4) — more drug and a much higher peak, so more sedation, though the peak itself arrives slightly later with food, not sooner. On the 2023 AGS Beers list to avoid in older adults. Its contraindication in significantly impaired liver function is about clearance rather than direct toxicity — LiverTox finds little evidence metaxalone itself injures the liver — but the label still directs great care and serial liver tests in anyone with pre-existing liver damage, so it is not a drug to treat as liver-neutral. Its older labels carry methocarbamol's wording — not for women who are or may become pregnant — while its newer FDA labels replaced that with a no-data risk summary noting rat studies showed no fetal effects, so which restriction applies depends on the manufacturer's label you are handed.

The liver risk here is real but is NOT a boxed warning — it sits in the Warnings section, which is easy to miss. The label states that “serious (including fatal) hepatocellular toxicity has been reported rarely,” that the mechanism appears idiosyncratic and unpredictable, and that the factors predisposing patients to it are not known — meaning there is no test to identify who is at risk beforehand. NIH's LiverTox groups chlorzoxazone with dantrolene as clearly linked to clinically apparent acute liver injury, including cases of acute liver failure and death. The label says to report fever, rash, loss of appetite, nausea, vomiting, fatigue, right-upper-quadrant pain, dark urine or jaundice immediately and stop the drug. Effects add to alcohol and other CNS depressants. On the 2023 AGS Beers list to avoid in older adults. Its pregnancy wording is weaker than methocarbamol's: safe use in pregnancy is not established, and the label says to use it in women of childbearing potential only when the prescriber judges the benefits to outweigh the risks. Unlike methocarbamol's, it cites no reports of fetal or congenital abnormalities.

The most anticholinergic of the group, and unusually its restrictions are absolute rather than cautionary: CONTRAINDICATED in glaucoma, prostatic hypertrophy or bladder-neck obstruction, pyloric or duodenal obstruction, stenosing peptic ulcer, cardiospasm (mega-esophagus) and myasthenia gravis. Cyclobenzaprine points the same anticholinergic direction but carries these as a caution, not a bar — worth knowing if one is being swapped for the other. Use it with caution in tachycardia, cardiac arrhythmias, coronary insufficiency and cardiac decompensation. It can cause light-headedness, dizziness or fainting. Safety of continuous long-term therapy is not established, and very rare cases of aplastic anaemia have been reported with orphenadrine, though the label states that no causal relationship has been established. Separately, because the safety of continuous long-term therapy is not established, the label recommends periodic blood, urine and liver-function monitoring if it is prescribed for prolonged use. On the 2023 AGS Beers list to avoid in older adults. One thing the 'not a controlled substance' line hides: its label states orphenadrine has been chronically abused for euphoric effects, and that mood-elevating effects can occur at therapeutic doses.